GlassScriptPhysician profile
Armond G Schwartz
NPI 1245290071
$5,449.26
in general payments reported to CMS, 2019-2025
29 companies · $842 in 2025
The $842 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $757 · 2020: $28.29 · 2021: $565 · 2022: $1,125 · 2023: $872 · 2024: $1,260 · 2025: $842.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,919 · Education: $54.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,919.24 |
| Education | $54.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,847.69 | 2021-2025 | Skyrizi, Rinvoq, Linzess |
| Celgene Corporation | $647.15 | 2021-2024 | Zeposia |
| Shire North American Group INC | $500.00 | 2019 | |
| Janssen Biotech, INC. | $479.18 | 2019-2025 | Tremfya, Stelara |
| E.R. Squibb & Sons, L.L.C. | $338.31 | 2021-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $194.87 | 2020-2025 | Entyvio, Eohilia |
| Merck Sharp & Dohme LLC | $192.94 | 2022-2024 | Dificid |
| Celltrion USA INC. | $182.40 | 2024-2025 | Vegzelma |
| Pfizer INC. | $151.42 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $107.82 | 2019-2025 | Xifaxan |
| Genzyme Corporation | $99.75 | 2022-2025 | |
| Janssen Scientific Affairs, LLC | $96.18 | 2019 | |
| Boston Scientific Corporation | $86.68 | 2023-2024 | Agile Esophageal, Trapezoid Rx |
| Novo Nordisk INC | $86.40 | 2021 | |
| Intercept Pharmaceuticals, INC. | $68.84 | 2022-2024 | Ocaliva |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $66.19 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $42.45 | 2022-2023 | |
| Qol Medical, LLC | $42.05 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $38.81 | 2022-2024 | Dupixent |
| Pentax of America, INC. | $26.84 | 2024 | Pentax Medical, Inspira, C2 Cryoballoon |
| Lilly USA, LLC | $24.83 | 2025 | Omvoh |
| Ardelyx, INC. | $24.48 | 2024 | Ibsrela |
| Amgen INC. | $20.89 | 2025 | Uplizna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.50 | 2023 | |
| Phathom Pharmaceuticals, INC. | $17.02 | 2024 | Voquezna |
| Enterra Medical, INC. | $16.89 | 2024 | |
| Cumberland Pharmaceuticals, INC. | $14.88 | 2019 | |
| Vivus LLC | $13.80 | 2024 | Qsymia |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$26,177.30 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Armond Schwartz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.